TABLE 3

Effect of flavonol glycosides and aglycones on CYP2B1 and CYP3A23 mRNA expression in primary cultures of rat hepatocytes

Primary cultures of rat hepatocytes were treated with a G. biloba extract (i.e., extract A, Table 1; 100 μg/ml), kaempferol-3-O-rutinoside (1.9 μg/ml), quercetin-3-O-rutinoside (4 μg/ml), isorhamnetin-3-O-rutinoside (0.6 μg/ml), kaempferol (6.3 μg/ml), quercetin (10.6 μg/ml), or isorhamnetin (4.1 μg/ml). Control hepatocytes were treated with culture medium (vehicle for the extract) or DMSO (0.1%, vehicle for the individual chemicals). Data are expressed as the mean ± S.E.M. fold-increase in mRNA expression (relative to the vehicle-treated control group) for hepatocyte cultures from three individual rats.


Treatment

Fold Increase Relative to Control
CYP2B1 mRNA
CYP3A23 mRNA
Kaempferol-3-O-rutinoside 0.5 ± 0.1 0.5 ± 0.2
Quercetin-3-O-rutinoside 1.1 ± 0.3 0.9 ± 0.1
Isorhamnetin-3-O-rutinoside 0.7 ± 0.2 0.7 ± 0.2
Kaempferol 0.9 ± 0.1 0.9 ± 0.1
Quercetin 1.6 ± 0.4 1.3 ± 0.2
Isorhamnetin 0.9 ± 0.1 0.9 ± 0.2
Ginkgo biloba extract
8.3 ± 1.7*
5.3 ± 0.3*
  • * Significantly different from the corresponding vehicle-treated control group (P < 0.05).